Thank you so much for your support! 🚀🔵
🔵 We are thrilled to introduce the newest member of our startup portfolio: ATLyphe AG - a preclinical stage biotechnology startup dedicated to enable safer hematopoietic cell transplantation for patients in need. 🔵 Together with their team, the co-founders Danielle Villars, Renier Myburgh and Maddalena Marconato are driving forward the development of their lead compound ALY117, a bispecific T cell engager, to transform the current approach to hematopoietic stem cell transplantation (HSCT). Besides being a USZ Startup, ATLyphe AG is a spin-off from ETH Zürich and from Universität Zürich | University of Zurich and is currently supported by Wyss Zurich. We look forward to supporting ATLyphe AG in their efforts to bring this novel and targeted conditioning to patients. 🚀 𝙇𝙚𝙩’𝙨 𝙞𝙢𝙥𝙧𝙤𝙫𝙚 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨‘ 𝙡𝙞𝙫𝙚𝙨. 𝙏𝙤𝙜𝙚𝙩𝙝𝙚𝙧. ▶ More about ATLyphe AG: https://lnkd.in/gwczGUjQ #atlyphe #uszinnovationandstartupcenter #uszstartup #healthcarestartup #hsct | Universitätsspital Zürich | Lukas Jaeger | Isabell von Loga